Recent Press Releases
Study finds elevated risk of certain rare blood cancers after chemotherapy for most solid tumorsDecember 20, 2018In a new study, NIH investigators found that patients treated with chemotherapy for most solid tumors had an increased risk of tMDS/AML, a rare but often fatal blood cancer. The study, which used population-based data, was published in JAMA Oncology.
Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemiaDecember 4, 2018A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.
Statement from NCI Director Dr. Norman E. Sharpless on the Death of Senator John McCainAugust 27, 2018Senator John McCain, a long-time supporter of cancer research, passed away on August 25.
NCI-led research team develops predictor for immunotherapy response in melanomaAugust 20, 2018In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.
Rosenberg, NCI-supported researchers to receive 2018 Albany PrizeAugust 15, 2018NCI’s Steven A. Rosenberg, M.D., Ph.D., and two NCI-supported researchers have been named recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering immunotherapy research.
Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancerAugust 14, 2018Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American menJuly 17, 2018RESPOND is the largest coordinated study on biological and non-biological factors associated with aggressive prostate cancer in African-American men. The study is an effort to learn why these men disproportionally experience aggressive disease.
NCI and VA collaborate to boost veterans’ access to cancer clinical trialsJuly 10, 2018NCI and the Department of Veterans Affairs (VA) are launching the NAVIGATE program at 12 VA facilities across the country to make it easier for veterans to participate in NCI-sponsored clinical trials.
New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatmentsJune 4, 2018A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.
NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapiesJune 4, 2018The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.
No hay comentarios:
Publicar un comentario